Bryan Giraudo - 02 Jan 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Bryan Giraudo
Issuer symbol
PTGX
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 19:41:45 UTC
Previous filing
02 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Giraudo Bryan Director C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK /s/ Matthew Gosling, Attorney-in-Fact for Bryan Giraudo 06 Jan 2026 0001740847

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +2,695 +18% $0.000000 17,825 02 Jan 2026 Direct F1
holding PTGX Common Stock 8,000 02 Jan 2026 By Bryan & Courtney Giraudo Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Award $0 +3,762 $0.000000 3,762 02 Jan 2026 Common Stock 3,762 $87.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date.
F2 The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.